Leading with innovation

Sanofi scientists think beyond individual diseases, exploring metabolic hubs where multiple diseases intersect. When our R&D teams close in on a molecule that modifies various biological pathways, they can create versatile medicines with the potential to treat more people and a higher chance of success in the clinic.

Emerging leadership in immunology and inflammation

Sanofi’s vibrant immunology and inflammation pipeline centers on allergic and inflammatory conditions driven by type 2 inflammation. The success of Dupixent®, our best-in-class biologic treatment, unleashed a flood of innovation throughout R&D as our scientists began to think bigger than a single drug and delve into every aspect of the type 2 inflammatory pathway.

  • In our long-standing collaboration with Regeneron, we initiated a pivotal trial of Dupixent® for patients with type-2-driven chronic obstructive pulmonary disease (COPD), while itepekimab, an investigational biologic, entered phase 3 clinical trials for former smokers with non-type-2 COPD.
  • When Principia Biopharma joined Sanofi, we expanded our development of TAILORED COVALENCY®-engineered BTK inhibitors with strong potential to treat autoimmune, type 2 inflammatory, and allergic diseases.
  • In our collaboration with Kymera, we intensified development of potential first-in-class small-molecule therapies designed to eliminate immune-disease targets from cells in patients with type 2 inflammatory diseases.

Our teams investigate unique molecules that target immunological pathways beyond type 2. For example, using SYNTHORIN™ technology, we engineered an investigational IL-2 molecule that helps regulate T cells. Our multi-specific NANOBODY® platform gave rise to new biologics that bind simultaneously to multiple targets, potentially overcoming a long-standing challenge in the treatment of immunological diseases. Our rich immunology portfolio crosses therapeutic areas, with important advances in oncology, hematology, and neurology.1

This work is progressing alongside a growing precision immunology program, which centers on the measurable experience of patients. By combining real-world data, genetics, genomics, and machine learning approaches, our teams are gaining a detailed, nuanced understanding of immune conditions to guide the development of precision therapeutics.

The tenacity, flexibility, and creativity of our scientists in 2020 was evident not only in immunoscience, but across all disease areas. Even as the roadmap of how we live and work changed, they ensured that neither clinical trials nor development timelines for potential new treatments were derailed by the pandemic. Pulling together across the organization and across sectors, they helped turn great science into new opportunities for patients and changed the future of medicine.

Find out more about: Immunology and Inflammation R&D

1 See Capital Markets Day 2021 presentation.
2 Dupixent® (dupilumab) is a product in collaboration with Regeneron. Dupixent® is approved for different patient populations with atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyps. It might not be approved in markets where you live, please check locally.

Voices from the Lab: Fine-tuning science

Sanofi scientist Samuel Pine talks about his commitment to discovering precision therapies for cancer patients, using NANOBODY® technologies.

Two vaccines in development to fight COVID-19

In 2020 Sanofi marshalled a broad-based attack on COVID-19 while protecting our long-term commitment to science. We launched two vaccine R&D programs in collaboration with other companies to increase our chances of success. By December, we had started developing recombinant-protein and mRNA vaccines, optimized our manufacturing capacities to be ready for broad supply, and embarked on clinical investigations to test the potential of existing drugs for treating severe COVID-19 disease. Throughout the crisis our R&D teams put patients and their needs first, with solutions including targeted direct-to-patient drug supply and telemedicine. As a result, 98% of our patients in over 500 clinical trials remained in the studies. Under intense pressure, they showed that by keeping patients at the center, and with a little creativity, they could reinvent clinical drug development.

Find out more about: